01—Abstract
Summary
Summary of the 10-K/A filed April 25, 2019. Cited figures are marked; the original filing is the authoritative source.
This 10-K filing from Moderna, Inc. as of April 25, 2019, focuses primarily on the company's corporate governance, executive compensation, and security ownership.
It highlights the composition and independence of the board of directors, including the separation of CEO and Chairman roles and the staggered board structure intended to provide stability. The filing details the compensation of named executive officers, showing significant stock option awards, particularly for the CEO, Stéphane Bancel, linked to the company's IPO. Additionally, it outlines the compensation structure for non-employee directors, emphasizing equity grants to align their interests with shareholders.
For investors, this filing provides insight into the leadership team's alignment with shareholder value through equity incentives. The details on board independence and committee structures suggest a commitment to good corporate governance.
Understanding these aspects is crucial for assessing the company's management team and their incentives as Moderna continues its development of mRNA-based therapeutics. The significant ownership stakes held by the CEO and major institutional investors like Flagship Pioneering also indicate a strong alignment of interests.
02—Key points
Key Highlights
- Moderna's board of directors is composed of nine members, with all non-employee directors deemed independent, demonstrating a commitment to robust corporate governance.
- The company has separated the roles of CEO (Stéphane Bancel) and Chairman of the Board (Noubar B. Afeyan), a structure the board believes is appropriate for current governance needs.
- Executive compensation, particularly for CEO Stéphane Bancel, includes substantial stock option awards, notably a large grant in December 2018 tied to the IPO, intended to align executive interests with shareholders.
- Named executive officers for 2018 included Stéphane Bancel (CEO), Lorence Kim (CFO), and former President John Mendlein, with compensation structures detailed, including base salary, bonuses, and significant equity awards.
- A new non-employee director compensation policy, effective December 2018, includes annual cash retainers and equity awards (stock options) designed to align director interests with long-term shareholder value.
- Major shareholders include Flagship Pioneering (17.9%), AstraZeneca (7.8%), and Viking Global Investors (5.2%), indicating significant institutional backing and influence.
- The CEO, Stéphane Bancel, holds a substantial beneficial ownership of 9.5% of the company's common stock, signaling strong personal investment in the company's success.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-K/AFY2018filed April 25, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $135.07M$205.82M | −34.4% |
| Cost of Revenue | $0— | — |
| Gross Profit | $135.07M— | — |
| R&D Expenses | $454.08M$410.46M | +10.6% |
| Operating Expenses | $548.33M$475.18M | +15.4% |
| Operating Income | -$413.27M-$269.36M | −53.4% |
| Net Income | -$384.73M-$255.92M | −50.3% |
| EPS (Basic) | $-4.95$-4.18 | −18.4% |
| Shares Outstanding (Basic) | 81.11M64.50M | +25.8% |
05—Questions
Frequently Asked Questions
What is the company's approach to corporate governance and board composition?
Moderna maintains a board of nine directors, with all non-employee directors identified as independent. The company has separated the roles of Chief Executive Officer and Chairman of the Board, believing this structure supports effective oversight. The board is also divided into three staggered classes to promote stability in leadership.
How is executive compensation structured, and how does it align with shareholder interests?
Executive compensation is overseen by the Compensation and Talent Committee, comprised of independent directors. A significant portion of executive pay, particularly for the CEO, is equity-based, including substantial stock option grants. For example, CEO Stéphane Bancel received a large stock option grant in late 2018, priced at the IPO level, to align his economic interests with those of public shareholders.
Who are the significant beneficial owners of Moderna's stock as of the filing date?
As of March 31, 2019, the largest beneficial owners included Flagship Pioneering and affiliated entities (17.9%), AstraZeneca and affiliated entities (7.8%), and Viking Global Investors LP and affiliated entities (5.2%). CEO Stéphane Bancel also held a significant stake of 9.5%.
What is the compensation for non-employee directors?
Moderna's non-employee directors receive both cash retainers and equity awards (stock options). The compensation structure, updated in late 2018, includes varying retainers based on board roles (e.g., Chairperson of a committee) and annual stock option grants to incentivize long-term performance and alignment with shareholders.
06—Continue